drugset / Trial / NCT01913353

A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®

NCT01913353

RandomizedParallel-groupSingle-blindPrevention

Summary

To demonstrate the efficacy of MVA-BN® in terms of vaccinia-specific Plaque Reduction Neutralization Test (PRNT) antibody response and by showing that vaccination prior to administration of ACAM2000® results in an attenuated take.

Timeline

Start
2015-03
Primary completion
2017-03
Completion
2017-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ACAM2000 Vaccine 0.0025 ml Other
Subject IMVAMUNE Vaccine 0.5 ml Subcutaneous

Indications

No indication recorded.